Intra-Cellular Therapies Files 2024 Annual Report Amendment
| Field | Detail |
|---|---|
| Company | Intra-Cellular Therapies, Inc. |
| Form Type | 10-K/A |
| Filed Date | Mar 20, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, annual-report, sec-filing
Related Tickers: ITCI
TL;DR
ITCI filed its 2024 10-K amendment on 3/20/25. Check for updates.
AI Summary
Intra-Cellular Therapies, Inc. filed an amendment (10-K/A) on March 20, 2025, for their fiscal year ending December 31, 2024. The company, located at 135 Route 202/206, Suite 6, Bedminster, NJ 07921, operates in the Pharmaceutical Preparations sector. This filing serves as an update to their annual report.
Why It Matters
This amendment provides updated financial and operational information for investors and regulatory bodies, reflecting the company's performance and status as of the end of the 2024 fiscal year.
Risk Assessment
Risk Level: low — This filing is an amendment to a standard annual report, not indicating new material risks.
Key Numbers
- 2024 — Fiscal Year End (The report covers the fiscal year ending December 31, 2024.)
- 20250320 — Filing Date (The amendment was filed on March 20, 2025.)
Key Players & Entities
- Intra-Cellular Therapies, Inc. (company) — Filer of the 10-K/A
- 001-36274 (company) — SEC file number
- 2024-12-31 (date) — Fiscal year end
- 2025-03-20 (date) — Filing date
- 135 ROUTE 202/206 SUITE 6 BEDMINSTER NJ 07921 (company) — Business and mailing address
FAQ
What is the purpose of this 10-K/A filing?
This filing is an amendment (No. 1) to the annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2024.
When was this amendment filed?
The amendment was filed on March 20, 2025.
What is the fiscal year end for this report?
The fiscal year end for this report is December 31, 2024.
What is the company's SEC file number?
The company's SEC file number is 001-36274.
What is the primary business address of Intra-Cellular Therapies, Inc.?
The business address is 135 ROUTE 202/206, SUITE 6, BEDMINSTER, NJ 07921.
Filing Details
This Form 10-K/A (Form 10-K/A) was filed with the SEC on March 20, 2025 regarding Intra-Cellular Therapies, Inc..